Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. (2nd June 2016)

• Record Type: Journal Article
• Authors: Nuki, Yoichiro; Esaki, Motohiro; Asano, Kouichi; Maehata, Yuji; Umeno, Junji; Moriyama, Tomohiko; Nakamura, Shotaro; Matsumoto, Takayuki; Kitazono, Takanari
• Is Part Of: Scandinavian journal of gastroenterology. Volume 51:Number 6(2016)
• Page Start: 700
• Page End: 705
• Publication Date: 2016-06-02
• Subjects: Infliximab -- short-term efficacy -- tacrolimus -- ulcerative colitis; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.3109/00365521.2016.1138239
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Objective Both tacrolimus (Tac) and infliximab (IFX) are effective for moderate-to-severe ulcerative colitis (UC). The aim of this study was to compare the therapeutic efficacy and safety of both drugs.Materials and methods We performed a retrospective analysis of 46 patients with moderate-to-severe UC who were treated either by Tac ( n = 21) or IFX ( n = 25). We compared the remission and response rates for 10 weeks between the two groups. In patients who achieved a clinical response, the subsequent relapse rate was compared. The overall adverse events were also compared between the two groups.Results The remission and response rates at week 10 did not differ between patients treated with Tac (67% and 86%, respectively) and patients treated with IFX (76% and 92%, respectively). Among 41 patients showing a clinical response, eight of 23 patients treated with IFX and eight of 18 patients treated with Tac showed a subsequent relapse. The risk of relapse was not different between the two groups. While no serious adverse events were observed, the incidence of adverse events was higher in patients treated with Tac than in those treated with IFX.Conclusion Tac and IFX may be equally efficacious for the induction and maintenance of remission in patients with UC while minor adverse events are more frequent with the former treatment.